TransTech Pharma, Inc. Obtains Exclusive License To Glucokinase Activator Program For The Treatment Of Diabetes From Novo Nordisk A/S

Published: Feb 21, 2007

HIGH POINT, N.C. & BAGSVAERD, Denmark--(BUSINESS WIRE)--TransTech Pharma and Novo Nordisk A/S (NYSE: NVO)(CSE: NVO) announced today an agreement whereby TransTech has obtained an exclusive license from Novo Nordisk to its clinical glucokinase activator (GKA) program. Tests in a variety of mammalian species suggest that glucokinase activators can help people with diabetes control their glucose levels. Under the terms of the agreement, TransTech will obtain all rights worldwide to Novo Nordisk’s GKA program including preclinical and clinical compounds, the latter with human data.

Back to news